article Open AccessTop 1% cited

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clinical Infectious Diseases · 2020 · Vol. 71(15) · pp. 732–739

Xueting Yao(Peking University Third Hospital)Fei Ye(National Institute for Viral Disease Control and Prevention)Miao Zhang(Peking University Third Hospital)Cheng Cui(Peking University Third Hospital)Baoying Huang(National Institute for Viral Disease Control and Prevention)Peihua Niu(National Institute for Viral Disease Control and Prevention)Xu Liu(Peking University)Li Zhao(National Institute for Viral Disease Control and Prevention)Erdan Dong(Peking University)Chunli Song(Peking University)Siyan Zhan(Peking University)Roujian Lu(National Institute for Viral Disease Control and Prevention)Haiyan Li(Peking University Third Hospital)Wenjie Tan(National Institute for Viral Disease Control and Prevention)Dongyang Liu✉(Peking University)

View via DOI Full-text PDF

Abstract

Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.

COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Vitamin C and Antioxidants ResearchHydroxychloroquineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe acute respiratory syndrome coronavirusMedicine2019-20 coronavirus outbreakDosingCoronavirusBetacoronavirusVirology

MeSH terms

BetacoronavirusCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntiviral AgentsCell LineChlorocebus aethiopsChloroquineHydroxychloroquineLungPneumonia, ViralVero CellsCoronavirus InfectionsSevere Acute Respiratory Syndrome